Company unveils advanced product features for Quell Wearable Pain Relief Technology at CES 2017, booth #43421 LAS VEGAS --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO, NUROW) today announced plans to unveil important advances to its Quell® Wearable Pain Relief Technology™ at CES 2017 (CES
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported strong interest in Quell coming out of last week's Consumer Electronics Show (CES). According to Frank McGillin , SVP and General Manager of Consumer Health at NeuroMetrix , "In the first several days that the
Key Step Towards Entering Consumer Healthcare Market WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its wearable technology for treatment of chronic pain received 510(k) clearance (K140333) from the U.S. Food and Drug Administration (FDA) for
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced that Jiro Nakamura , M.D., Ph.D., has joined its Scientific Advisory Board . Dr.
The smart wearable harnessing the power of neurostimulation and AI to attack the chronic pain crisis LAS VEGAS, Jan. 07, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix Inc. (Nasdaq: NURO) today unveiled its smartest, smallest and most powerful wearable therapeutic to date.
WALTHAM, Mass. , Jan. 17, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today a collaboration with GlaxoSmithKline (NYSE:GSK), one of the world's largest science-led global healthcare companies, involving Quell ® Wearable Pain Relief Technology™.
WALTHAM, Mass --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, has been featured in several media
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, has been featured in several media outlets that spotlighted the Company and the SENSUS ™ Pain
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NASDAQ : NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 13,800 shares of Series C convertible preferred stock at
